| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H16ClNO4 |
| Molecular Weight | 309.745 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(COC(C)(C)C(O)=O)OC(=N1)C2=CC=C(Cl)C=C2
InChI
InChIKey=LNXXSBRGLBOASF-UHFFFAOYSA-N
InChI=1S/C15H16ClNO4/c1-9-12(8-20-15(2,3)14(18)19)21-13(17-9)10-4-6-11(16)7-5-10/h4-7H,8H2,1-3H3,(H,18,19)
Romazarit, (Ro 31-3948, 7), 2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methylpropionic acid is a substituted heterocyclic alkoxypropionic acid. Romazarit was considered to be a potential disease-modifying antirheumatic drug. Romazarit was withdrawn due to its toxicity profile.
Originator
Approval Year
Doses
Sourcing
PubMed
Patents
Sample Use Guides
patients with rheumatoid arthritis:
200 mg or 450 mg every 12 h for up to 24 weeks,
100 mg t.i.d., 350 mg b.i.d., or 350 mg t.i.d., for 6 days.
Route of Administration:
Oral
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
